Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

WHITE PLAINS, N.Y., Feb. 19, 2013 /PRNewswire/ -- In 1964, the five-year survival rate for the most common form of childhood leukemia was only three percent but, today, thanks to treatment advances, about 90 percent of children survive. As the leading global non-profit organization dedicated to curing blood cancers, The Leukemia & Lymphoma Society (LLS) has invested nearly one billion dollars in blood cancer research since 1954, bringing us closer than ever to realizing a world without blood cancers.

(Photo:  http://photos.prnewswire.com/prnh/20130219/NY61444 )

LLS has achieved its leadership position through a unique approach to research and fundraising. Its venture philanthropy model forges partnerships with pharmaceutical and biotechnology companies, academia, medical centers and the National Institutes of Health, to foster the process of drug discovery from basic research to translational and clinical research. Rather than duplicate what the federal government is funding, LLS developed its own research agenda to accelerate the development of promising new life-saving therapies with a focus on un-met medical need.

"We're not your grandfather's charity," proclaims Louis DeGennaro , PhD, LLS chief mission officer. "There is no means of preventing or early screening for blood cancers, so our focus is on life-saving research to find cures. LLS research funding has touched the discovery or development of nearly every therapy used in the battle against blood cancers – including targeted drugs, like Gleevec®, Velcade® and Kyprolis™, and immunotherapies, like Rituxan®."

In fact, LLS is playing a unique role in the pathway to cures, especially for a non-profit organization.  Blood cancers, which include leukemia, lymphoma, myeloma and myelodysplastic syndromes, are hema
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... of rod-shaped metal nanoparticles in water with ultrasound and ... bits. Why? No one yet knows exactly. But researchers ... have clocked their speedand it,s fast. At up to ... faster than any nanoscale object submerged in liquid ever ... opened up the possibility that they could be used ...
(Date:7/22/2014)... 2014 Automated cell culture systems are ... cell culture. They allow production of optimum cells at ... in drug discovery and industries and biopharmaceutical companies. Cell ... iPSC research, cryobanking, cell-based assays, and cellular expression systems ... Analysts forecast the Global Cell Culture market ...
(Date:7/22/2014)... 2014  Neogen Corporation (NASDAQ: NEOG ) ... which ended May 31, increased 19% from the previous ... compared to the prior year,s $27,190,000. Adjusted for a ... share in the current year were $0.76, compared to ... for the 2014 fiscal year established new all-time highs ...
(Date:7/22/2014)... , July 22, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper announces Pullman Regional Hospital,s ... first EPA-registered antimicrobial solid touch surface, at a nominal ... of MRSA, E-coli and other bacteria within 2 hours of ... protecting against bacteria and infectious diseases in its facilities. ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... , , LAKE MARY, Fla., ... Inc. (NasdaqCM: NGBF) today announced that on August 26, 2009, ... staff indicating that, based on the Company,s stockholders equity as ... the quarter ended June 30, 2009, the Company is no ...
... , BALTIMORE, Md., Aug. 27 Champions Biotechnology, ... development of advanced preclinical platforms and tumor specific data to ... results for the fiscal year ended April 30, 2009. Full ... Company,s Form 10-K available at www.championsbiotechnology.com. , , ...
... , , MURRIETA, Calif., Aug. ... announce the expansion of its US operations. Copan Diagnostics, Inc. ... plastic transfer pipet and additional medical device manufacturing operations to ... addition of blow molding machinery and filling and packing equipment ...
Cached Biology Technology:New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements 2Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results 2Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results 3Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results 4Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results 5Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2
(Date:7/22/2014)... computer science and engineering professor with an expertise in ... Science Foundation grant worth more than $600,000 to develop ... fly., Heng Huang, an associate professor, will lead the ... Arlington Computer Science and Engineering department. Scientists are compiling ... large number of genes involved in fruit fly development ...
(Date:7/22/2014)... 2014) New research from the Monell Center reveals ... can increase airway inflammation in asthmatics for at least ... that expectations can play in health-related outcomes. , "Asthmatics ... expect that an odor is harmful, our bodies react ... lead author Cristina Jan, PhD, a Monell physiologist. "Both ...
(Date:7/22/2014)... not be good for the average steak, but it ... prepare to survive Alaska,s winter cold. , "Alaska wood ... a steak does in your freezer and the frog ... shape than the steak," said Don Larson, University of ... recent paper demonstrating that freeze tolerance in Alaska wood ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2In asthma, it's not just what you smell, but what you think you smell 2In asthma, it's not just what you smell, but what you think you smell 3Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3
... Laval’s Faculty of Medicine have discovered that a ... a pathological reaction in skin cells. Guillaume Morissette, ... about the mode of action of this substance—called ... of Dermatology. , DMAE (2-dimethylaminoethanol) is used in ...
... 15 percent of couples of childbearing age struggle with the ... hope with Cornell researchers' identification of a mutation in a ... the first time that a dominant mutation that leads specifically ... say they can now look for similar mutations in the ...
... made a breakthrough by detecting the electrical equivalent of ... a step closer to both seeing the ‘heartbeat?of a ... , To stay alive, individual biological cells must ... membranes. This flow produces an electrical current that could, ...
Cached Biology News:Anti-wrinkle compound causes pathological reaction in skin cells 2Researchers find gene mutation that causes infertility in male mice 2A new study of living cells could revolutionize the way we test drugs 2
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic acid stain has also found uses ... bandshift assays. A 500 µL unit size (S-7563) ...
... cross-linking techniques are defined by the author ... Wong. This valuable hardcover guide includes hundreds ... application references. More than 300 pages detail ... conjugate preparation from selection and design ...
... protein separation by two-dimensional electrophoresis (2D-PAGE), ... package from Bio-Rad and protein identification ... to meet customers requirements regarding experimental ... format of the results permanent contact ...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: